159 related articles for article (PubMed ID: 31870185)
1. Developments in drug design strategies for bromodomain protein inhibitors to target
Nguyen HHT; Yeoh LM; Chisholm SA; Duffy MF
Expert Opin Drug Discov; 2020 Apr; 15(4):415-425. PubMed ID: 31870185
[No Abstract] [Full Text] [Related]
2. Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit
Sosa Y; Deniskin R; Frame IJ; Steiginga MS; Bandyopadhyay D; Graybill TL; Kallal LA; Ouellette MT; Pope AJ; Widdowson KL; Young RJ; Akabas MH
ACS Infect Dis; 2019 Oct; 5(10):1738-1753. PubMed ID: 31373203
[TBL] [Abstract][Full Text] [Related]
3. Antiplasmodial drug targets: a patent review (2000 - 2013).
Okombo J; Chibale K
Expert Opin Ther Pat; 2016; 26(1):107-30. PubMed ID: 26566576
[TBL] [Abstract][Full Text] [Related]
4. Why is the Plasmodium falciparum hexose transporter a promising new drug target?
Joët T; Morin C; Fischbarg J; Louw AI; Eckstein-Ludwig U; Woodrow C; Krishna S
Expert Opin Ther Targets; 2003 Oct; 7(5):593-602. PubMed ID: 14498822
[TBL] [Abstract][Full Text] [Related]
5. Diversity-oriented synthesis probe targets Plasmodium falciparum cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors.
Lukens AK; Heidebrecht RW; Mulrooney C; Beaudoin JA; Comer E; Duvall JR; Fitzgerald ME; Masi D; Galinsky K; Scherer CA; Palmer M; Munoz B; Foley M; Schreiber SL; Wiegand RC; Wirth DF
J Infect Dis; 2015 Apr; 211(7):1097-103. PubMed ID: 25336726
[TBL] [Abstract][Full Text] [Related]
6. Advances in omics-based methods to identify novel targets for malaria and other parasitic protozoan infections.
Cowell AN; Winzeler EA
Genome Med; 2019 Oct; 11(1):63. PubMed ID: 31640748
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
Deniskin R; Frame IJ; Sosa Y; Akabas MH
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
[TBL] [Abstract][Full Text] [Related]
8. Purine and pyrimidine pathways as targets in Plasmodium falciparum.
Cassera MB; Zhang Y; Hazleton KZ; Schramm VL
Curr Top Med Chem; 2011; 11(16):2103-15. PubMed ID: 21619511
[TBL] [Abstract][Full Text] [Related]
9. Screening and In Vitro Evaluation of Potential Plasmodium falciparum Leucyl Aminopeptidase Inhibitors.
Chaudhary M; Singh V; Anvikar AR; Sahi S
Curr Comput Aided Drug Des; 2016; 12(4):282-293. PubMed ID: 27449897
[TBL] [Abstract][Full Text] [Related]
10. The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs.
Herman JD; Pepper LR; Cortese JF; Estiu G; Galinsky K; Zuzarte-Luis V; Derbyshire ER; Ribacke U; Lukens AK; Santos SA; Patel V; Clish CB; Sullivan WJ; Zhou H; Bopp SE; Schimmel P; Lindquist S; Clardy J; Mota MM; Keller TL; Whitman M; Wiest O; Wirth DF; Mazitschek R
Sci Transl Med; 2015 May; 7(288):288ra77. PubMed ID: 25995223
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages.
Ke H; Ganesan SM; Dass S; Morrisey JM; Pou S; Nilsen A; Riscoe MK; Mather MW; Vaidya AB
PLoS One; 2019; 14(4):e0214023. PubMed ID: 30964863
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum.
Kortagere S; Welsh WJ; Morrisey JM; Daly T; Ejigiri I; Sinnis P; Vaidya AB; Bergman LW
J Chem Inf Model; 2010 May; 50(5):840-9. PubMed ID: 20426475
[TBL] [Abstract][Full Text] [Related]
13. Viability Screen of LOPAC
Tong JX; Ang SEL; Tan EHN; Tan KSW
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718250
[TBL] [Abstract][Full Text] [Related]
14. Dephospho-Coenzyme A Kinase Is an Exploitable Drug Target against Plasmodium falciparum: Identification of Selective Inhibitors by High-Throughput Screening of a Large Chemical Compound Library.
Nurkanto A; Imamura R; Rahmawati Y; Prabandari EE; Waluyo D; Annoura T; Yamamoto K; Sekijima M; Nishimura Y; Okabe T; Shiba T; Shibata N; Kojima H; Duffy J; Nozaki T
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0042022. PubMed ID: 36314787
[TBL] [Abstract][Full Text] [Related]
15. [Transport proteins as drug targets in Plasmodium falciparum. New perspectives in the treatment of malaria].
Ellekvist P; Colding H
Ugeskr Laeger; 2006 Mar; 168(13):1314-7. PubMed ID: 16579884
[TBL] [Abstract][Full Text] [Related]
16. Peptide Probes for
Saunders CN; Cota E; Baum J; Tate EW
ACS Chem Biol; 2020 Jun; 15(6):1313-1320. PubMed ID: 32383851
[TBL] [Abstract][Full Text] [Related]
17. Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes.
Magistrado PA; Corey VC; Lukens AK; LaMonte G; Sasaki E; Meister S; Wree M; Winzeler E; Wirth DF
ACS Infect Dis; 2016 Nov; 2(11):816-826. PubMed ID: 27933786
[TBL] [Abstract][Full Text] [Related]
18. The Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic Screens.
Hapuarachchi SV; Cobbold SA; Shafik SH; Dennis AS; McConville MJ; Martin RE; Kirk K; Lehane AM
PLoS Pathog; 2017 Feb; 13(2):e1006180. PubMed ID: 28178359
[TBL] [Abstract][Full Text] [Related]
19. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
[TBL] [Abstract][Full Text] [Related]
20. Editorial: antimalarial drug discovery and design in the era of resistance.
Bell A
Curr Pharm Des; 2013; 19(2):264-5. PubMed ID: 22973889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
